PHARMOCANN GLOBAL LTD Inactive Instrument
Pharmocann Global Ltd Share Price TEL AVIV STOCK EXCHANGE
Equities
PMCN
IL0010968902
Healthcare Facilities & Services
| Sales 2022 | 22.66M 6.04M 481M | Sales 2023 | 14.41M 3.84M 306M | Capitalization | 3.12M 833K 66.28M |
|---|---|---|---|---|---|
| Net income 2022 | -25M -6.67M -531M | Net income 2023 | -9M -2.4M -191M | EV / Sales 2022 | 0.4 x |
| Net cash position 2022 | 925K 247K 19.64M | Net cash position 2023 | 768K 205K 16.31M | EV / Sales 2023 | 0.16 x |
| P/E ratio 2022 |
-0.26
x | P/E ratio 2023 |
-0.28
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 51.05% |
More Fundamentals
* Assessed data
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 40 | 16/06/19 | |
Daniel Spira
AUD | Comptroller/Controller/Auditor | 69 | 28/12/19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Guy Sigura
CHM | Chairman | 47 | 04/12/22 |
Locar Gila
BRD | Director/Board Member | 51 | 28/11/22 |
| Director/Board Member | 43 | 28/11/22 |
Medical Compression System DBN Ltd is an Israel-based company active in the medical sector. It is engaged in the research, development, production and marketing of non-invasive and non-medicinal solutions to improve the blood flow processes, using a pneumatic device which places pressure on the limbs by means of compressed air. The technology developed by the Company facilitates reducing the risk of blood clots forming during traumatic and surgical events, and secular diseases. It also completed the development of a pneumatic device for preventing the formation of blood clots in the deep veins system as the result of a trauma or surgical intervention, which is called the ActiveCare DVT.
| 1st Jan change | Capi. | |
|---|---|---|
| +29.90% | 272M | |
| +44.86% | 261M | |
| +50.00% | 194M | |
| +43.48% | 131M | |
| -28.57% | 121M | |
| +115.91% | 119M | |
| -36.75% | 119M | |
| 0.00% | 86.82M | |
| +150.00% | 75.33M |
